Advertisement
Advertisement

GILD

GILD logo

Gilead Sciences Inc

129.26
USD
Sponsored
+1.51
+1.18%
Apr 28, 15:59 UTC -4
Closed
exchange

After-Market

128.90

-0.36
-0.28%

Gilead Sciences Inc Profile

About

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

Info & Links

CEO

Daniel P. O�Day

Headquarters

333 LAKESIDE DRIVE
FOSTER CITY, CA 94404, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.gilead.com

Auditor

Ernst & Young LLP

Share holders

1,305

Employees

17,000

Gilead Sciences Inc Statistics

Valuation Measures

Market Capitalization2

159.99B

Enterprise Value

177.36B

Enterprise Value/EBITDA(ttm)

13.88

Price to Earnings Ratio(ttm)

17.43

Price to Sales(ttm)

5.99

Price to Book(mrq)

7.79

Price to Cash(ytd)

13.57

Profitability

Gross Margin(ttm)

78.75%

Operating Margin(ttm)

34.74%

Profit Margin(ttm)

28.56%

Return on Equity(ttm)

49.46%

Return on Invested Capital(ttm)

19.77%

Return on Assets(ttm)

17.81%

Income Statement

Revenue(ttm)

29.44B

Revenue Per Share(ttm)

23.72

Gross Profit(ttm)

23.21B

EBITDA(ttm)3

12.78B

Net Income Available to Common(ttm)

8.51B

Diluted EPS(ttm)

6.77

Share Statistics

Beta (5Y Monthly)

0.39

52-Week Change

25.29%

S&P 500 52-Week Change

29.12%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

1.24B

Dividend Yield

2.31%

Float4

1.24B

% Held by Insiders

0.30%

% Held by Institutions

83.67%

Balance Sheet

Total Cash(mrq)

7.63B

Total Cash Per Share(mrq)

6.15

Total Debt(mrq)

24.94B

Total Debt/Equity(mrq)

110.25%

Current Ratio(mrq)

1.55%

Quick Ratio(mrq)

1.40%

Book Value Per Share(mrq)

18.23

Cash Flow

Operating Cash Flow Per Share(ytd)

7.98

Free Cash Flow(ytd)

9.46B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement